2016年上半年美国FDA批准的新分子实体与评价:神经系统疾病、呼吸系统疾病、皮肤病治疗用药和造影剂被引量：3

Updates of New Molecular Entities Approved by the FDA in the First-Half of 2016:Neurology,Respiratory,Skin Disordersand Imaging Agents

下载PDF

导出

摘要 2016年上半年,FDA批准了14个新分子实体和新生物制品。本文介绍和评价神经系统疾病、呼吸系统疾病、皮肤病治疗用药和造影剂。 The US FDA approved14new molecular entities and new therapeutic biological products in the first-half of2016.This article provides an update and evaluation of the new drugs approved for the treatment of neurology,respiratory and skin diseases,and imaging agents.

作者孙树森韩容赵志刚 SUN Shu-sen;HAN Rong;ZHAO Zhi-gang(College of Pharmacy, Western New England University, Springfield, MA 01119, United States;Department of Pharmacy, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100050, China)

机构地区美国西新英格兰大学药学院首都医科大学附属北京天坛医院药学部

出处《药品评价》 CAS 2017年第4期12-17,共6页 Drug Evaluation

基金 "药物管理平台"子课题国家科技部"脑血管病创新药物临床评价技术平台"重大专项基金编号:2008ZX09312-00

关键词 FDA 2016年新分子实体神经系统呼吸系统皮肤病造影剂 FDA 2016 Newmolecular entity Neurology Respiratory Skin Imaging Agents

分类号 R97 [医药卫生—药品]

引文网络
相关文献

参考文献3

1孙树森,马翔,韩容,赵志刚.2014年美国FDA批准的新分子实体与评价:消化系统疾病,神经系统疾病,银屑病和罕见病治疗用药以及造影剂[J].药品评价,2015,12(6):6-12. 被引量：6
2孙树森,韩容,赵志刚.2015年上半年美国FDA批准的新分子实体与评价:消化系统疾病、皮肤病、感染和罕见病治疗用药[J].药品评价,2015,12(14):5-10. 被引量：11
3孙树森,赵志刚.2015年下半年美国FDA批准的新分子实体与评价:呼吸、血液和代谢系统疾病治疗用药以及解毒剂[J].药品评价,2016,13(4):12-19. 被引量：2

二级参考文献59

1奈妥吡坦,中自洛诺司琼药品说明书[OL].Akynzeowebsite,,https://www.akynzeo.com/media/Prescribing-Information.pdf,2014-40-30/2015,1-6.
2Schwartzberg L. Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting[J]. Expert Rev Pharmacoecon Outcomes Res, 2014, 14(6): 825-834.
3Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancerpain[J]. N Engl J Med Overseas Ed, 2014, 370(25): 2387-2396.
4Garnock-Jones KP. Naloxegol: a review of its use in patients withopioid-induced constipation[J]. Drugs,2015,75(4):419-425.
5Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med Overseas Ed, 2013, 369(8): 699-710.
6Sandborn W J, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease[J]. N Engl J Med Overseas Ed, 2013, 369(8): 711-721.
7Sands BE, Feagan BG, Rutgeerts P, et aL Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed[J]. Gastroenterology, 2014, 147(3): 618-627.e3.
8Smith MA, Mohammad RA. Vedolizumab: an alpha4beta7 integrin inhibitor for inflammatory bowel diseases[J]. Ann Pharmacother, 2014, 48(12): 1629-1635.
9Connor K, Budd K, Snavely D, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial(trial #l)[J]. JOURNAL OF SLEEP RESEARCH, 2012, 2I: 97-97.
10lvgy-May N, Leibensperger H, Froman S, et al. Efficacy and safety of suvorexant, an urexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial(trial #2)[J]. JOURNAL OF SLEEP RESEARCH, 2012, 21: 351-352.